Smartest $400 Dividend Stocks to Buy Now

Are dividend stocks a good investment? I recommend Warren Buffett. Buffett's Berkshire Hathaway is full of dividend stocks. He's one of the smartest investors ever. Buy amazing dividend stocks without a billionaire. You can buy numerous dividend-paying stocks with little money upfront. The best $400 dividend stocks to purchase now are alphabetized below.  

1. AresCapital You may not know Ares Capital (NASDAQ: ARCC). But U.S. middle-market corporations are. Ares Capital is the largest publicly traded middle market BDC. Stock is cheap in two ways. First, Ares Capital's stock is under $21. Second, the stock has a forward price-to-earnings ratio of 8.6, which is low for any industry.  

The ultrahigh dividend yield of over 9.4% makes Ares Capital stand out. The BDC appears to be able to maintain dividends. Its track record is good. Ares Capital has paid a stable or growing quarterly dividend for 14 years.  

Since its 2004 IPO, Ares Capital's average total return has outperformed the S&P 500 due to its robust dividend. The private capital market grows. Ares Capital's skills and reputation should keep it at the top of its market. I predict years of high overall returns from the stock.  

2. Enterprise Product Partners Enterprise Products Partners (NYSE: EPD) leads U.S. midstream energy. The limited partnership (LP) transports crude oil, natural gas, and NGLs across the country via nearly 50,000 miles of pipes. Multiple Enterprise Products Partners units under $30 won't require $400 upfront. Midstream-energy leader has an excellent price with a forward-earnings multiple of below 11.  

Enterprise Products Partners faces tax issues while investing in LPs. I think the company's above 7% dividend yield justified the extra tax preparation. I also like that Enterprise has increased distribution for 25 years. With climate change driving renewable energy use, is Enterprise Products Partners a good long-term investment? I guess so. Oil and gas demand will undoubtedly rise despite renewable energy deployment.  

3. Pfizer Many investors are familiar with Pfizer (NYSE: PFE). The drugmaker is among the largest. The company has several blockbuster medications and vaccines. This huge pharma stock trades at $27, making it inexpensive. Pfizer's sharp fall since late 2021 has increased its value. Forward-earnings multiple for the drugmaker is just over 12.1.  

Investors have also benefited from Pfizer's poor stock performance. The company's 6.2% dividend yield is near a decade high.  

Pfizer could grow faster than its current issues indicate in the next years. By 2030, the business expects new product releases and indications to generate $20 billion in revenue. It seeks $25 billion in yearly revenue from business development projects by 2030.  

stay turned for development